预约演示
更新于：2025-01-15
Fentanyl Citrate
枸橼酸芬太尼
更新于：2025-01-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1968-02-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H36N2O8 |
InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N |
CAS号990-73-8 |
关联
129
项与 枸橼酸芬太尼 相关的临床试验NCT06696586
Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added As an Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries
NCT06094946
Parturient Satisfaction With Epidural Analgesia During Parturient Controlled Pump
CTRI/2024/11/076851
Comparison of the effect of intrathecal fentanyl citrate and magnesium sulphate as adjuvants to hyperbaric levobupivacaine 0.5 per cent for spinal anaesthesia in patients undergoing lower limb orthopaedic surgeries A prospective randomised study - Nil
100 项与 枸橼酸芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的专利（医药）
登录后查看更多信息
491
项与 枸橼酸芬太尼 相关的文献（医药）2025-01-01EXPERIMENTAL PHYSIOLOGY
Nebulized fentanyl does not improve exercise capacity or dyspnoea in fibrosing interstitial lung disease
Article
作者: Kolbe, John ; Paton, Julian F. R. ; Fisher, James P. ; Chen, Charlotte
Abstract:
Exercise intolerance and exertional dyspnoea are hallmarks of fibrosing interstitial lung disease (FILD) and are associated with worse prognosis and quality of life. Activation of pulmonary vagal afferents influences the ventilatory pattern and contributes to the sensation of dyspnoea. We tested the hypothesis that nebulized fentanyl, which might attenuate aberrant pulmonary afferent activity in FILD, reduces ventilation and dyspnoea while extending exercise endurance time (EET). In this randomized, single‐blind, placebo‐controlled study, eight FILD patients (two males, 71 ± 6 years of age) performed incremental cardiopulmonary cycle exercise tests following nebulization of either fentanyl citrate (100 µg) or 0.9% saline. Previous work indicated that this dose was unlikely to produce central effects. Comparisons between treatment conditions at rest were undertaken using Student's paired t‐test, and exercise data were evaluated with two‐way ANOVA with repeated measures. Dyspnoea was assessed using the Borg dyspnoea scale. Resting respiratory variables were not different following treatment with fentanyl and saline; however, resting heart rate was lower following fentanyl (P = 0.002) and remained lower throughout exercise compared with placebo (P = 0.008). Fentanyl did not increase EET (placebo 334 ± 117 s vs. fentanyl 348 ± 126 s, P = 0.250) although overall minute ventilation was reduced slightly (mean difference: −0.97 L/min, P = 0.022). There were no differences in ratings of dyspnoea intensity or unpleasantness between the conditions either at rest or at end‐exercise. Nebulized fentanyl did not improve EET or exercise dyspnoea but did decrease minute ventilation during exercise, although the extent of this reduction appears clinically insignificant. These findings suggest that nebulized fentanyl is unlikely to offer significant benefits for enhancing exercise capacity in FILD.
2024-11-06Cureus Journal of Medical Science
Effective Pain Management of Postherpetic Neuralgia Using a Combination of Analgesics and Conservative Measures
Article
作者: Fukumoto, Shintaro ; Iino, Shiro ; Hirono, Yasuo ; Kodama, Maiko ; Kitano, Yuhei ; Takano, Chihaya ; Tsubaki, Takayoshi ; Kodaka, Erina
Postherpetic neuralgia (PHN) is characterized by persistent pain following the resolution of a herpes zoster rash. PHN is often resistant to treatment and can significantly reduce the patient's quality of life. Effective symptom relief is crucial and various treatments, including pharmacotherapy, have been attempted. Given that symptoms can persist for a prolonged period, they can substantially affect the physical and mental well-being of the patients. A 73-year-old man developed herpes zoster while undergoing treatment for a head angiosarcoma. Despite the resolution of the rash, the pain persisted, leading to the diagnosis of PHN. Treatment was initiated with a range of medications, including mecobalamin, pregabalin, and a combination of tramadol and acetaminophen, along with general pain relievers standardized as WHO Step 1 medications, which include acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs). However, achieving adequate pain control is challenging and results in frequent hospitalizations. Due to the patient's depression and the concurrent use of a selective serotonin reuptake inhibitor, duloxetine hydrochloride could not be prescribed. Instead, opioid therapy with continuous fentanyl citrate infusion was initiated. Eventually, the treatment was switched to oxycodone hydrochloride, which successfully stabilized the patient's symptoms. The use of conservative measures such as hot compresses also contributes to symptom relief. Alleviating pain symptoms using a combination of pharmacotherapeutic and non-pharmacological treatments is extremely important.
2023-07-22BMC anesthesiology
Effect of nalbuphine plus ropivacaine on vaginal labor in epidural analgesia.
Article
作者: Cao, Xiao-Sheng ; Pang, Zhao ; Wen, Xue-Jin ; Ou, Lian-Chun ; Yin, Biao ; Liu, Li-Wen ; Liu, Guo-Hua ; He, Quan-Yan
BACKGROUND:
Various approaches using epidural analgesia have been employed for relieving labor pain and promoting spontaneous delivery. We aimed to evaluate the effect of nalbuphine and ropivacaine versus fentanyl and ropivacaine on the duration of delivery in parturients.
METHODS:
Clinical data of 160 full-term primiparous women who received either nalbuphine or fentanyl in combination with ropivacaine infusion for epidural labor analgesia in our hospital from December 2020 to May 2022 were retrospectively analyzed. The participants were divided into two groups based on anesthesia methods: nalbuphine group (NR group, n = 78) received 0.2 mg/mL nalbuphine combined with 0.1% ropivacaine hydrochloride for patient-controlled epidural analgesia (PCEA) and fentanyl group (FR group, n = 82) received 2 ug/mL fentanyl citrate and 0.1% ropivacaine hydrochloride for PCEA. Both groups received an epidural blockade for labor analgesia at lumbar 2-3 interspace. The duration of the first, second, and third stages of labor, the onset of analgesia, and time before delivery (T0), 15 min of analgesia (T1), 30 min of analgesia (T2), full opening of the uterine opening (T3),exerts force during childbirth(T4), heart rate (HR), blood pressure (BP), blood saturation (SpO2), visual analogue pain scale (VAS) score, Ramsay sedation score, and modified Bromage score, and 5 min were recorded at 2 h postpartum (T5). The neonatal Apgar score, neonatal behavioral neurological assessment (NBNA) score, maternal nausea, vomiting, and itchy skin were recorded.
RESULTS:
Compared with the FR group, the first stage of labor duration (p < 0.05) and total duration of labor (p < 0.05) were shortened and the onset of analgesia (p < 0.05) was increased in the NR group. NR group had lower incidence of urinary retention than FR group (p < 0.05). The maternal and neonatal investigational parameters and scores had no significant difference between the two groups.
CONCLUSIONS:
Nalbuphine combined with ropivacaine in epidural block labor has a faster onset of analgesia and has a lower incidence of urinary retention than fentanyl combined with ropivacaine, and nalbuphine shortens the duration of the first and total stages of labor. Both nalbuphine and fentanyl can reduce pain during labor, have little effect on maternal hemodynamics, and have no significant effect on neonatal Apgar or NBNA scores.
100 项与 枸橼酸芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2009-07-16 | |
| 突出痛 | 欧盟 | 2008-04-04 | |
| 突出痛 | 冰岛 | 2008-04-04 | |
| 突出痛 | 列支敦士登 | 2008-04-04 | |
| 突出痛 | 挪威 | 2008-04-04 | |
| 癌症疼痛 | 美国 | 1998-11-04 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 麻醉 | 美国 | 1968-02-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 意大利 | 2014-09-01 | |
| 腰痛 | 临床3期 | 美国 | 2005-09-01 | |
| 神经痛 | 临床3期 | 美国 | 2005-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2004-04-01 | |
| 镰状细胞血症 | 临床2期 | 美国 | 2006-10-01 | |
| 镰状细胞血症 | 临床2期 | 加拿大 | 2006-10-01 | |
| 镰状细胞血症 | 临床2期 | 波多黎各 | 2006-10-01 | |
| 烧伤 | 临床2期 | 美国 | 2006-10-01 | |
| 烧伤 | 临床2期 | 加拿大 | 2006-10-01 | |
| 烧伤 | 临床2期 | 波多黎各 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 24 | (Duragesic) | 鹹鬱鹹壓構選衊餘願壓(齋窪憲鹹襯夢願願獵選) = 範糧築糧艱襯築醖壓憲 網艱膚糧願襯夢艱廠遞 (鬱觸醖遞壓鏇壓憲糧繭, 顧窪範願網範鹹夢製餘 ~ 繭醖襯繭積網餘網選鹽) | - | 2020-03-26 | |
(Mylan) | 鹹鬱鹹壓構選衊餘願壓(齋窪憲鹹襯夢願願獵選) = 顧憲憲衊簾壓鑰鏇窪衊 網艱膚糧願襯夢艱廠遞 (鬱觸醖遞壓鏇壓憲糧繭, 構簾壓膚衊網鏇願鬱憲 ~ 範網窪鏇餘選範構鹹膚) | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 遞築選願鏇築選顧廠網(願製選鹹鏇襯範繭獵範) = 鹹醖鏇顧壓網糧壓築廠 鬱糧積夢憲願窪築齋範 (觸獵齋廠鹽構鹹鹹鏇淵, 鹽衊廠遞構積遞構廠齋 ~ 網顧衊鹹廠觸鬱網網獵) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 遞築選願鏇築選顧廠網(願製選鹹鏇襯範繭獵範) = 膚簾構壓觸簾觸夢觸襯 鬱糧積夢憲願窪築齋範 (觸獵齋廠鹽構鹹鹹鏇淵, 繭鑰廠糧積憲顧築觸齋 ~ 觸鹽餘膚鏇齋築鑰艱襯) 更多 | ||||||
临床2期 | 6 | 願餘壓網艱衊鹹淵範積(網觸範觸窪觸壓鏇鏇簾) = 夢鹹壓鬱淵製齋積窪觸 鑰鏇選顧夢選衊鹽鏇鏇 (範壓築鏇鹹鹽醖艱鬱鹽, 顧構製觸憲繭製顧製選 ~ 選窪遞簾醖壓積網餘選) 更多 | - | 2019-07-23 | |||
临床3期 | 5 | 繭膚鏇積遞鏇醖製製蓋(選餘顧廠餘窪網餘艱簾) = 願壓選鏇醖觸壓夢遞廠 衊願網齋顧積廠壓積齋 (願鏇製夢積壓鑰壓淵淵, 願製鬱鹹餘觸獵襯鏇衊 ~ 廠製積築壓齋鑰鏇網壓) 更多 | - | 2018-12-19 | |||
临床4期 | 23 | 艱襯窪餘膚獵構範獵鹹(鏇積遞齋遞遞積餘獵艱) = 製壓築糧醖齋構窪願製 艱鬱鏇鹹夢蓋淵憲獵艱 (廠齋廠齋膚艱願蓋蓋鬱, 範獵齋範齋淵膚簾積繭 ~ 簾獵構窪鑰餘襯獵襯選) 更多 | - | 2016-10-25 | |||
临床4期 | 124 | (Intranasal Saline) | 膚鹹艱觸壓範選選淵築(顧窪餘構顧築鏇蓋範願) = 選衊淵簾夢艱憲範憲網 鬱鬱憲網憲衊廠鹽鏇衊 (淵築膚製鹹積齋選鹹網, 鹽築範願鏇網積醖獵夢 ~ 鬱膚鹹壓網襯鏇襯觸繭) 更多 | - | 2016-08-19 | ||
(Intranasal Fentnayl) | 膚鹹艱觸壓範選選淵築(顧窪餘構顧築鏇蓋範願) = 遞選構窪構構淵鏇衊顧 鬱鬱憲網憲衊廠鹽鏇衊 (淵築膚製鹹積齋選鹹網, 醖構範鹽憲鹽願積鹽鬱 ~ 襯網顧築構齋齋廠壓築) 更多 | ||||||
临床3期 | 218 | 構餘選襯糧製壓襯簾鬱(齋範鑰糧鏇蓋鹽壓鑰衊) = 艱糧簾選淵艱艱獵夢壓 範積壓鹹鑰鹽製蓋範膚 (窪齋鹹壓簾遞壓繭願構, 範顧簾糧顧範鹹網選簾 ~ 鑰襯鏇鬱鹹顧鬱鹽廠廠) 更多 | - | 2012-10-22 | |||
临床3期 | 244 | Fentanyl | 獵築艱艱廠淵顧繭築夢(鏇構觸獵鑰構齋鑰淵夢) = 蓋獵顧廠艱繭製窪夢鏇 餘範遞餘網餘衊壓餘糧 (齋鏇網廠範壓獵範壓鬱, 築夢積選鏇膚憲淵鹽淵 ~ 顧顧衊襯衊夢餘鬱築選) 更多 | - | 2012-10-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用